Spots Global Cancer Trial Database for Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Official Title: Phase I Trial of Sorafenib in Combination With Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Study ID: NCT00544609
Conditions
Study Description
Brief Summary: Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Detailed Description: Study phase I in patients with Invasive Bladder Cancer
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital Clínic i Provincial de Barcelona, Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, , Spain
Institut Català d' Oncología, Barcelona, , Spain
Contact Details
Name: Xavier García del Muro Solans, MD
Affiliation: Institut Català d' Oncología, Barcelona
Role: STUDY_CHAIR
Name: Salvador Villà Freixa, MD
Affiliation: Institut Català d' Oncología, Barcelona
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
